Taxopac Injection 6 mg/ml contains Paclitaxel, a chemotherapeutic agent belonging to the taxane class, used in the treatment of a variety of cancers. Paclitaxel is particularly effective for breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and other solid tumors. It works by stabilizing microtubules, thereby preventing cell division and inducing apoptosis in rapidly dividing cancer cells. Taxopac is administered intravenously under strict medical supervision, either alone or in combination with other chemotherapy agents, making it a cornerstone of modern oncologic therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Uses and Benefits

• Breast Cancer: Effective in adjuvant, neoadjuvant, and metastatic settings.

• Ovarian Cancer: Used alone or in combination with platinum-based agents for advanced disease.

• Non-Small Cell Lung Cancer (NSCLC): Administered as part of combination chemotherapy for advanced or metastatic disease.

• Other Solid Tumors: Effective in gastric, esophageal, and head & neck cancers depending on clinical protocols.

• Cell Division Inhibition: Paclitaxel interferes with microtubule function, halting mitosis and promoting cancer cell death.

• Combination Therapy: Enhances therapeutic efficacy when combined with other chemotherapeutic agents.

Mechanism of Action

Paclitaxel binds to microtubules, stabilizing them and preventing depolymerization. This action disrupts normal mitotic spindle formation, leading to cell cycle arrest in the M-phase and triggering apoptosis in rapidly proliferating tumor cells.

Dosage and Administration

• Route: Intravenous infusion only.

• Concentration: 6 mg/ml solution for dilution prior to infusion.

• Dosage: Determined by body surface area, type of cancer, and prior therapies. Typical doses range from 135–175 mg/m² administered over 3–24 hours depending on the regimen.

• Administration: Infuse under hospital or oncology clinic supervision. Pre-medication with corticosteroids, antihistamines, and H2 blockers is recommended to reduce hypersensitivity reactions.

• Treatment Cycle: Usually repeated every 2–3 weeks depending on the chemotherapy protocol.

• Monitoring: Frequent blood counts, liver function tests, and assessment for infusion-related reactions are essential.

Precautions and Safety Information

• Medical History: Inform your doctor if you have liver impairment, low blood counts, cardiac disorders, or known hypersensitivity to taxanes.

• Pregnancy and Lactation: Contraindicated; avoid pregnancy during treatment. Effective contraception is required.

• Hypersensitivity Reactions: Pre-medication is mandatory. Emergency care must be available during infusion.

• Drug Interactions: Certain medications affecting liver enzymes may alter Paclitaxel metabolism. Dose adjustments may be necessary.

Possible Side Effects

Taxopac Injection may cause both common and serious side effects, including:

• Hematologic: Neutropenia, leukopenia, anemia, thrombocytopenia

• Gastrointestinal: Nausea, vomiting, diarrhea, mucositis

• Neurological: Peripheral neuropathy, fatigue, myalgia

• Hypersensitivity: Rash, fever, chills, or allergic reactions

• Fluid Retention: Edema or weight gain (less common)

• Rare: Cardiac complications, liver toxicity

Side effects are managed with supportive care, dose adjustments, and close monitoring.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store vials at 2–8°C (refrigerated).

• Protect from light and freezing.

• Keep out of reach of children.

Taxopac Injection 6 mg/ml is a high-potency chemotherapeutic agent for managing multiple cancer types. When administered under strict medical supervision, it effectively inhibits tumor growth, improves survival, and complements combination chemotherapy regimens.